Physician profile
Madelyn Mcclellan
NPI 1043945504
$3,298.80
in general payments reported to CMS, 2019-2025
20 companies · $48.82 in 2025
The $48.82 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $632 · 2023: $2,240 · 2024: $377 · 2025: $48.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,666.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $673.49 | 2022-2025 | Watchman Access System, Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $617.74 | 2022-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $390.22 | 2022-2025 | Eliquis, Camzyos |
| Amgen INC. | $337.75 | 2023-2024 | Repatha |
| Merck Sharp & Dohme LLC | $274.70 | 2022-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $262.05 | 2022-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $138.90 | 2023-2024 | |
| Zoll Circulation INC | $110.05 | 2023 | Therox Ds2 Console, Catheter, Downstream Cartridge |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.06 | 2023 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $81.20 | 2023 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $65.94 | 2022-2024 | Farxiga |
| Pfizer INC. | $56.60 | 2023-2024 | |
| Kiniksa Pharmaceuticals, LTD. | $53.16 | 2022-2023 | Arcalyst |
| Esperion Therapeutics, INC. | $29.28 | 2023 | Nexletol |
| Heartflow, INC. | $24.31 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $23.14 | 2023 | Edarbi |
| Atricure, INC. | $22.91 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $20.84 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $20.76 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $12.70 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madelyn Mcclellan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.